Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:35 UTC
HMDB IDHMDB0014359
Secondary Accession Numbers
  • HMDB14359
Metabolite Identification
Common NameTorasemide
DescriptionTorasemide, also known as demadex or luprac, belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups. Torasemide is a strong basic compound (based on its pKa). torasemide can be converted into torasemide through the action of the enzyme solute carrier family 22 member 6. In humans, torasemide is involved in torsemide action pathway. An N-sulfonylurea obtained by formal condensation of pyridine-3-sulfonic acid with the free amino group of N-isopropylurea.
Structure
Data?1582753169
Synonyms
ValueSource
1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)ureaChEBI
DemadexChEBI
LupracChEBI
N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamideChEBI
TorasemidaChEBI
TorasemidumChEBI
TorsemideChEBI
1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulphonyl)ureaGenerator
N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulphonamideGenerator
1-Isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)ureaHMDB
Chemical FormulaC16H20N4O3S
Average Molecular Weight348.42
Monoisotopic Molecular Weight348.125611216
IUPAC Name1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
Traditional Nametorsemide
CAS Registry Number56211-40-6
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1
InChI Identifier
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
InChI KeyNGBFQHCMQULJNZ-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinesulfonamides
Direct ParentPyridinesulfonamides
Alternative Parents
Substituents
  • Pyridine-3-sulfonamide
  • Dihydropyridine
  • Toluene
  • Sulfonylurea
  • Monocyclic benzene moiety
  • Hydropyridine
  • Benzenoid
  • Secondary ketimine
  • Heteroaromatic compound
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Sulfonyl
  • Aminosulfonyl compound
  • Carboximidic acid derivative
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organic oxide
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Organic oxygen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point164 - 164 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.06 g/LNot Available
LogP2.3Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.06 g/LALOGPS
logP1.76ALOGPS
logP1.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.19 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.89 m³·mol⁻¹ChemAxon
Polarizability36.15 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+180.49131661259
DarkChem[M-H]-181.92731661259
DeepCCS[M+H]+185.01630932474
DeepCCS[M-H]-182.65830932474
DeepCCS[M-2H]-216.84330932474
DeepCCS[M+Na]+192.15730932474
AllCCS[M+H]+182.032859911
AllCCS[M+H-H2O]+179.132859911
AllCCS[M+NH4]+184.732859911
AllCCS[M+Na]+185.532859911
AllCCS[M-H]-179.432859911
AllCCS[M+Na-2H]-179.532859911
AllCCS[M+HCOO]-179.832859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
TorasemideCC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C14140.2Standard polar33892256
TorasemideCC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C12522.9Standard non polar33892256
TorasemideCC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C12985.3Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Torasemide,1TMS,isomer #1CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)=C12953.6Semi standard non polar33892256
Torasemide,1TMS,isomer #1CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)=C12892.4Standard non polar33892256
Torasemide,1TMS,isomer #1CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)=C14339.3Standard polar33892256
Torasemide,1TMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)=C12932.3Semi standard non polar33892256
Torasemide,1TMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)=C12812.9Standard non polar33892256
Torasemide,1TMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)=C14353.9Standard polar33892256
Torasemide,1TMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C)=C12847.2Semi standard non polar33892256
Torasemide,1TMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C)=C12817.8Standard non polar33892256
Torasemide,1TMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C)=C14066.5Standard polar33892256
Torasemide,2TMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C12776.7Semi standard non polar33892256
Torasemide,2TMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13001.4Standard non polar33892256
Torasemide,2TMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13774.2Standard polar33892256
Torasemide,2TMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C12899.1Semi standard non polar33892256
Torasemide,2TMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13071.2Standard non polar33892256
Torasemide,2TMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13993.8Standard polar33892256
Torasemide,2TMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)[Si](C)(C)C)=C12746.3Semi standard non polar33892256
Torasemide,2TMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)[Si](C)(C)C)=C12965.8Standard non polar33892256
Torasemide,2TMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13912.5Standard polar33892256
Torasemide,3TMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C12774.6Semi standard non polar33892256
Torasemide,3TMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13236.3Standard non polar33892256
Torasemide,3TMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C13580.2Standard polar33892256
Torasemide,1TBDMS,isomer #1CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)=C13204.2Semi standard non polar33892256
Torasemide,1TBDMS,isomer #1CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)=C13129.3Standard non polar33892256
Torasemide,1TBDMS,isomer #1CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)=C14308.6Standard polar33892256
Torasemide,1TBDMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C13196.8Semi standard non polar33892256
Torasemide,1TBDMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C13030.3Standard non polar33892256
Torasemide,1TBDMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C14325.1Standard polar33892256
Torasemide,1TBDMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C13060.1Semi standard non polar33892256
Torasemide,1TBDMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C13030.9Standard non polar33892256
Torasemide,1TBDMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C14102.5Standard polar33892256
Torasemide,2TBDMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13219.4Semi standard non polar33892256
Torasemide,2TBDMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13450.4Standard non polar33892256
Torasemide,2TBDMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13834.2Standard polar33892256
Torasemide,2TBDMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13396.3Semi standard non polar33892256
Torasemide,2TBDMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13520.9Standard non polar33892256
Torasemide,2TBDMS,isomer #2CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C14032.1Standard polar33892256
Torasemide,2TBDMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13208.5Semi standard non polar33892256
Torasemide,2TBDMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13389.6Standard non polar33892256
Torasemide,2TBDMS,isomer #3CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13955.5Standard polar33892256
Torasemide,3TBDMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13434.8Semi standard non polar33892256
Torasemide,3TBDMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13916.0Standard non polar33892256
Torasemide,3TBDMS,isomer #1CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C13729.6Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Torasemide GC-MS (Non-derivatized) - 70eV, Positivesplash10-001i-7922000000-38709aad9fb92fea20e12017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Torasemide GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Torasemide GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-03di-0090000000-bcaf4981571fb662df862017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-03di-0090000000-00cc7369c05298ea1c972017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-03di-0490000000-60171fe07a2f255596e32017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-01ot-2950000000-359d6835f9bf703a07012017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-000t-3910000000-a5ec65a6dbedfe7a30d32017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-0564-6900000000-051171526b146f5d076c2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOFsplash10-03di-0190000000-1b2efe76058c7bf06b4a2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-03di-0091000000-548edfa45514c501788d2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-03di-0090000000-d7326b2b38380cd06e262017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-03di-0490000000-b9f43c4768937947d77f2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-001i-0940000000-7b7084526f7c13bf64432017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-00lr-0910000000-81aa8c9ff5d9a3cd3c102017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-0159-0900000000-87860a9931a8414432cf2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide , positive-QTOFsplash10-03di-1590000000-1b7d966c20cec1451f6c2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide , positive-QTOFsplash10-03di-0490000000-bd8b6af3fe8d0f10e1172017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide , positive-QTOFsplash10-02ai-2940000000-5beb0e7e25d3939038032017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOFsplash10-03di-0390000000-314819093d7d5a1f48f42017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide 30V, Negative-QTOFsplash10-03di-0090000000-6b7078f4aeb0a91558662021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Torasemide 15V, Negative-QTOFsplash10-03di-0090000000-11bcaf88b642f06fcc7e2021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Torasemide 10V, Positive-QTOFsplash10-01ot-2069000000-943a38503d89c086bae72016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Torasemide 20V, Positive-QTOFsplash10-0bt9-8191000000-b93ec223bde95bf1c7382016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Torasemide 40V, Positive-QTOFsplash10-0a4l-9210000000-19f11559fea4b58be1cf2016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Torasemide 10V, Negative-QTOFsplash10-0002-3269000000-93ec6053a659f34ee77f2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Torasemide 20V, Negative-QTOFsplash10-06si-1490000000-5dfeefbdd22794dac7392016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Torasemide 40V, Negative-QTOFsplash10-0a4l-9430000000-1d7767a4763c0a30541a2016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00214 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00214 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00214
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID38123
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkTorasemide
METLIN IDNot Available
PubChem Compound41781
PDB IDNot Available
ChEBI ID9637
Food Biomarker OntologyNot Available
VMH IDTMD
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212 ]
  2. Authors unspecified: FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. [PubMed:8197389 ]

Enzymes

General function:
Involved in peroxidase activity
Specific function:
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells.
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular weight:
68685.82
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular weight:
55627.365
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular weight:
55944.565
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular weight:
55824.275
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

General function:
Involved in transport
Specific function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular weight:
121449.1
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608 ]
  3. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. [PubMed:10406837 ]